$56.22
1.85% yesterday
Nasdaq, Jun 13, 10:01 pm CET
ISIN
US09061G1013
Symbol
BMRN

Biomarin Pharmaceutical Stock price

$56.22
-3.56 5.96% 1M
-9.79 14.83% 6M
-9.51 14.47% YTD
-28.02 33.26% 1Y
-49.54 46.84% 5Y
-65.71 53.89% 10Y
+49.78 772.98% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-1.06 1.85%
ISIN
US09061G1013
Symbol
BMRN
Sector
Industry

Key metrics

Market capitalization $10.78b
Enterprise Value $10.10b
P/E (TTM) P/E ratio 21.14
EV/FCF (TTM) EV/FCF 16.29
EV/Sales (TTM) EV/Sales 3.43
P/S ratio (TTM) P/S ratio 3.65
P/B ratio (TTM) P/B ratio 1.86
Revenue growth (TTM) Revenue growth 19.36%
Revenue (TTM) Revenue $2.95b
EBIT (operating result TTM) EBIT $712.04m
Free Cash Flow (TTM) Free Cash Flow $620.18m
Cash position $1.27b
EPS (TTM) EPS $2.66
P/E forward 16.12
P/S forward 3.43
EV/Sales forward 3.22
Short interest 2.78%
Show more

Is Biomarin Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Biomarin Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Biomarin Pharmaceutical forecast:

25x Buy
81%
6x Hold
19%

Analyst Opinions

31 Analysts have issued a Biomarin Pharmaceutical forecast:

Buy
81%
Hold
19%

Financial data from Biomarin Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,950 2,950
19% 19%
100%
- Direct Costs 607 607
18% 18%
21%
2,344 2,344
20% 20%
79%
- Selling and Administrative Expenses 897 897
5% 5%
30%
- Research and Development Expense 701 701
10% 10%
24%
746 746
235% 235%
25%
- Depreciation and Amortization 34 34
25% 25%
1%
EBIT (Operating Income) EBIT 712 712
302% 302%
24%
Net Profit 524 524
155% 155%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Biomarin Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomarin Pharmaceutical Stock News

Positive
The Motley Fool
9 days ago
It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high.
Positive
Finbold
15 days ago
The second half of 2025 is fast approaching, and the stock market is promising a crazy ride with some exciting news hitting the headlines.
Neutral
Business Wire
24 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inozyme Pharma, Inc. (NasdaqGS: INZY) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Inozyme will receive $4.00 in cash for each share of ...
More Biomarin Pharmaceutical News

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Head office United States
CEO Alexander Hardy
Employees 3,040
Founded 1997
Website www.biomarin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today